STAT Plus: Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Trying to sell stock now on the down-low reveals a harsher truth about Cel-Sci and is an ominous tell for the fate of its immunotherapy.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario